Literature DB >> 9789819

Muscarinic acetylcholine receptors activate the acetylcholinesterase gene promoter.

R M Nitsch1, S Rossner, C Albrecht, M Mayhaus, J Enderich, R Schliebs, M Wegner, T Arendt, H von der Kammer.   

Abstract

The acetylcholinesterase (AChE) gene promoter contains several overlapping binding sites for Sp1 and Egr-1 transcription factors. Cotransfection experiments and promoter assays showed that Egr-1 can potently activate transcription from the human AChE promoter. Muscarinic acetylcholine receptors (mAChR) rapidly activate, via protein kinase C-mediated signaling, expression of the Egr-1 gene, leading to dramatically increased nuclear concentrations of Egr-1 protein, and to increased binding of Egr-1 to specific DNA recognition sequences. These mAChR-induced increases are followed by increased transcription from the human AChE promoter. In vivo studies with intraventricular infusions of the cholinergic immunotoxin 192 IgG saporin showed more than 80% decrease of AChE activity in cholinergic target areas of the hippocampus and brain cortex. The results are compatible with a combination of decreased AChE activity in degenerating subcortical cholinergic projections, and additional decreases in postsynaptic AChE gene expression. Together our data show that mAChR can activate transcription from the AChE promoter via increased synthesis of Egr-1. The results suggest a feedback mechanism by which the AChE gene is activated by cholinergic neurotransmission, possibly leading to increased formation of AChE protein and accelerated degradation of acetylcholine at cholinergic synapses. This possibility suggests testing of cholinomimetic compounds currently in development for the treatment of Alzheimer's disease for their potential ability to increase AChE gene expression.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9789819     DOI: 10.1016/s0928-4257(98)80029-6

Source DB:  PubMed          Journal:  J Physiol Paris        ISSN: 0928-4257


  8 in total

1.  APP and APLP2 are essential at PNS and CNS synapses for transmission, spatial learning and LTP.

Authors:  Sascha W Weyer; Maja Klevanski; Andrea Delekate; Vootele Voikar; Dorothee Aydin; Meike Hick; Mikhail Filippov; Natalia Drost; Kristin L Schaller; Martina Saar; Miriam A Vogt; Peter Gass; Ayan Samanta; Andres Jäschke; Martin Korte; David P Wolfer; John H Caldwell; Ulrike C Müller
Journal:  EMBO J       Date:  2011-04-26       Impact factor: 11.598

Review 2.  Not just amyloid: physiological functions of the amyloid precursor protein family.

Authors:  Ulrike C Müller; Thomas Deller; Martin Korte
Journal:  Nat Rev Neurosci       Date:  2017-03-31       Impact factor: 34.870

3.  Switching From Donepezil to Rivastigmine Is Well Tolerated: Results of an Open-Label Safety and Tolerability Study.

Authors:  Carl H Sadowsky; Martin R Farlow; Leone Atkinson; Jennifer Steadman; Barbara Koumaras; Michael Chen; Dario Mirski
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

4.  Changes in the activity and protein levels of CSF acetylcholinesterases in relation to cognitive function of patients with mild Alzheimer's disease following chronic donepezil treatment.

Authors:  T Darreh-Shori; L Meurling; T Pettersson; K Hugosson; E Hellström-Lindahl; N Andreasen; L Minthon; A Nordberg
Journal:  J Neural Transm (Vienna)       Date:  2006-08-01       Impact factor: 3.575

5.  In-depth characterization of the neuroinflammatory reaction induced by peripheral surgery in an animal model.

Authors:  Konstanze Plaschke; Sara Schulz; Rebecca Rullof; Markus A Weigand; Jürgen Kopitz
Journal:  J Neural Transm (Vienna)       Date:  2018-07-23       Impact factor: 3.575

6.  Different cholinesterase inhibitor effects on CSF cholinesterases in Alzheimer patients.

Authors:  Agneta Nordberg; Taher Darreh-Shori; Elaine Peskind; Hilkka Soininen; Malahat Mousavi; Gina Eagle; Roger Lane
Journal:  Curr Alzheimer Res       Date:  2009-02       Impact factor: 3.498

7.  Targeted Promoter Replacement Reveals That Herpes Simplex Virus Type-1 and 2 Specific VP16 Promoters Direct Distinct Rates of Entry Into the Lytic Program in Sensory Neurons in vivo.

Authors:  Richard L Thompson; Nancy M Sawtell
Journal:  Front Microbiol       Date:  2019-07-24       Impact factor: 5.640

8.  Delirium Accompanied by Cholinergic Deficiency and Organ Failure in a 73-Year-Old Critically Ill Patient: Physostigmine as a Therapeutic Option.

Authors:  Benedikt Zujalovic; Eberhard Barth
Journal:  Case Rep Crit Care       Date:  2015-10-13
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.